RxDoctor Payments Data

Rachel Gougian, DO

Family Medicine · University Park, MDNPI 1528420387

Payments from drug & device makers

$1,009in general payments, 2019–2025

Across 26 payments — averaging $38.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$289
  • Novo Nordisk$197
  • Astellas Pharma US Inc$174
  • Axsome Therapeutics, Inc.$130
  • Kvk-tech, Inc.$129
  • Amgen$38
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$81681%
  • Education$19319%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC9$289
Novo Nordisk5$197
Astellas Pharma US Inc3$174
Axsome Therapeutics, Inc.4$130
Kvk-tech, Inc.1$129
Amgen2$38
Exact Sciences1$29
TMS Neurohealth Centers Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,009 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$16,655
Medicare patients
39
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$115,330
JardianceEmpagliflozin55$68,644
OzempicSemaglutide61$63,812
BiktarvyBictegrav/Emtricit/Tenofov Ala11$42,099
JanuviaSitagliptin Phosphate16$19,114
Atorvastatin Calcium225$1,866
Chlorthalidone66$1,507
Albuterol Sulfate HfaAlbuterol Sulfate63$1,306
Amlodipine Besylate144$1,129
Duloxetine Hcl30$1,119
Diclofenac Sodium28$892
Wixela InhubFluticasone Propion/Salmeterol17$881
Omeprazole26$818
Metformin Hcl68$736
Losartan Potassium84$735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$289$115,33095 claims
Novo NordiskOzempic$197$63,81261 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in University Park

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →